BioSyntech Signs a Collaborative Agreement With Novartis Ophthalmics Inc.Business Editors LAVAL, Quebec--(BUSINESS WIRE)--July 12, 2001 BioSyntech, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :BSYI) has signed a collaborative agreement with Novartis Ophthalmics Inc., the eye health unit of Novartis AG (NYSE NYSE See: New York Stock Exchange :NVS NVS - Non-Volatile Storage ) to develop sustained release formulation for one of Novartis' compounds using BioSyntech's patented technology BST-Gel(TM). "We at BioSyntech are very excited about this agreement. Novartis Ophthalmics is a world leader in discovery and commercialization of Ophthalmic products. Its support shows confidence in our platform BST-GelTM technology," said company Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. , Dr. Ajay Gupta. BIOSYNTECH, an advanced biomaterials company specializing in tissue repair and biotherapeutic delivery products. THIS PRESS RELEASE CONTAINS CERTAIN "FORWARD-LOOKING" STATEMENTS, AS DEFINED IN THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and OF 1995 THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES. THERE CAN BE NO ASSURANCE THAT SUCH STATEMENTS WILL PROVE TO BE ACCURATE AND THE ACTUAL RESULTS AND FUTURE EVENTS COULD DIFFER MATERIALLY FROM MANAGEMENT'S CURRENT EXPECTATIONS. SUCH FACTORS ARE DETAILED FROM TIME TO TIME IN THE COMPANY'S FILINGS WITH THE REGULATORY AUTHORITIES HAVING JURISDICTION. NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion